Home / Transcripts / Paysign, Inc. (PAYS) · March 24, 2026

Paysign, Inc. (PAYS) Earnings Call Transcript

March 24, 2026

NASDAQ US Financials Financial Services earnings 47 min

Earnings Call Speaker Segments

Mark Newcomer executive
#1

Kevin, thank you. Good day, everyone, and I'm glad you could join us for Paysign's earnings call covering the close of 2025. I'm Mark Newcomer, President and Chief Executive Officer. Jeff Baker, our Chief Financial Officer, is here alongside me. Additionally, Matt Turner, who leads Patient Affordability as President, and Matt Lanford, our Chief Payments Officer, are on the line — following our prepared comments, both gentlemen will take part in Q&A. We issued our financial results for the fourth quarter and the entire 2025 year earlier today, and those results reflected enduring strength together with extraordinary expansion in each key metric. Revenue for the whole year climbed 40.5%, reaching $82 million. We saw net income nearly double, rising 98% to $7.6 million. Adjusted EBITDA increased 107%, reaching $19.9 million. A really important point: operating margins expanded by 723 basis points. That's solid proof we've reached a major turning point, one where additional revenue going forward ought to translate into greater operating leverage and better profitability. And our patient affordability business continues to post impressive growth. Looking at the past year, our total revenue climbed 168% compared to the prior year, reaching $33.9 million, up from $12.7 million in 2024. The number of claims we handled grew by roughly 79%. For anyone just getting familiar with what we do, our patient affordability platform is designed to help drug companies make sure patients can obtain expensive medications through the operation of co-pay assistance programs. During 2025, our platform was responsible for delivering close to $1 billion in financial assistance to patients, which helped more than 840,000 people gain access to high-cost therapies. Beyond that, we assist manufacturers in gaining tighter control over how those funds are used, and that stands as one of the main value propositions we offer. What sets our platform apart is our dynamic business rules technology, which enables pharmaceutical manufacturers to steer clear of needless expenses tied to co-pay maximizer programs. Just during 2025, the solution generated more than $325 million in savings for our clients, and so far this year we've already delivered close to $150 million in savings for them. That magnitude of savings is a real economic win for our customers and really shows what our platform is worth. Over the course of the year we brought on 55 programs, which took our total number of active programs up to 131, spanning over 70 patient affordability clients. Revenue growth, both near-term and longer-term, came from a combination of transition programs and new launches. Retail pharmacy, specialty pharmacy, and products given in-office, whether administered or infused, are all covered by our programs. Cancer treatment products and other oncology offerings continue to make up a big share of our program base, and across the platform, biologics account for roughly 50% of claim volume. Growth inside our current customer base remains robust. Take, for instance, the country's biggest drug makers — after bringing one aboard back in 2024, those initiatives grew well across 2021. On top of that, we brought in 4 more programs from that very same manufacturer over the course of the year. Growth of this kind among major pharma customers shows how well our platform scales and how steady the demand is. At present, Paysign runs live programs with 6 of the 10 highest-revenue U.S. pharmaceutical manufacturers. We'll be at Asembia's Specialty Pharmacy Summit in Las Vegas next month. Just like in earlier years, potential customers looking at what we offer are showing considerable enthusiasm, and we're heading into this conference with a solid pipeline. During the last few months, we've spoken with shareholders, analysts and prospective investors so they can gain a clearer picture of the patient affordability business and the wider industry landscape where we work. More and more, those conversations have brought up subjects tied to legislation, regulation and policy. So I figured it would be useful to have Matt Turner, who serves as our President of Patient Affordability, share some further background.

Matt Turner executive
#2

Thanks, Mark. Before I get into a few of the questions that have come our way from investors and analysts regarding possible headwinds facing our business, I'd like to take a moment to walk through where our Patient Affordability business sits inside the larger health care ecosystem. What our platform does is help pharmaceutical manufacturers enable patient access to high-cost branded therapies, mainly among patients who are commercially insured. These tend to be branded medications whose out-of-pocket costs can be substantial, and where co-pay assistance programs play an essential role in getting patients started on therapy and keeping them on it. In parallel, our platform enables manufacturers to exercise better control over how those assistance dollars get used, especially in a setting where payer dynamics can create inefficiencies in the system; that blend of widening access while also generating economic value is what drives demand for what we offer; with that as background, I'll take on a few of the areas we've been asked about. First, the growth of direct-to-consumer, also called DTC, along with cash pay models. Programs like these have been around in one form or another for more than 10 years and aren't new; they were designed mainly for products that have little or no commercial insurance coverage. That segment looks very different from the one we serve now. When it comes to the kinds of high-cost branded therapies on our platform, where list prices can reach tens of thousands of dollars — roughly 90% of the drugs on our platform — cash pay and discount alternatives just aren't a workable answer for the majority of patients. Commercial insurance paired with manufacturer co-pay assistance continues to be the model that works best for patients. So we see DTC expansion as a complementary option in certain situations; it is not, however, a meaningful replacement for our core business. Second, on pharmacy discount programs like GoodRx, TrumpRx, Cost Plus or comparable offerings. Such products have been on the market for over 20 years and play a valuable role in lowering costs for lower-priced generic medications or for patients who lack insurance; they aren't built for branded specialty medications — nor do they compete with them — where commercial insurance and co-pay programs represent the standard of care. Our business is focused squarely on that branded drug segment and on the more than 850 specialty drugs. So these programs just aren't relevant to what we do. Third, and maybe most importantly, given where policy stands right now on legislative and regulatory matters, most activity concerning co-pay accumulator and maximizer programs has happened at the state level. And in spite of continuing discussions and congressional committees, no meaningful federal action has occurred to date, and we don't anticipate any in the foreseeable future. The main explanation is structural. Since a large share of commercially insured Americans receive coverage through employer-sponsored health plans governed by ERISA, which constrains the reach of state-level regulations, we don't see that shifting. Consequently, these programs keep operating even as state laws change. What's key here is that appetite for our dynamic business rule offerings — the ones that assist manufacturers in dealing with maximizer programs — keeps expanding. As Mark mentioned, we've already delivered savings of nearly $150 million for our clients during this year, money that those programs would have taken otherwise. Taking a step back, we're still watching both the competitive and regulatory environments carefully. Yet judging by current conditions, we don't see these forces as a significant risk to what we do. If anything, they keep strengthening the case for offerings such as ours, and that shows up in how our business and pipeline keep growing. Our distinctive dynamic business rules strength is generating concrete ROI for our pharma clients, all while we improve affordability for hundreds of thousands of consumers. Over to you, Mark.

Mark Newcomer executive
#3

Thanks, Matt. Now, regarding our business that compensates plasma donors. During 2025, revenue from plasma compensation came to $45.6 million, which was up 4% compared with $43.9 million in 2024. Our expectation is that this business will keep showing revenue growth, mostly from filling excess capacity at existing centers instead of opening new ones. Even so, we do anticipate a modest number of new centers opening in 2026, which keeps our market share at just under 50%. We finished 2025 with 595 centers, which is 115 more than the prior year, and we remain in discussions with the other plasma collection companies that are not yet our customers. We think the broader set of donor management and engagement tools that we bought last year opens up further chances to expand our presence in this area. While we wait for FDA 510(k) review of our donor management system, which is also called a BECCS or Blood Establishment Computer System, we are working hard to integrate the BECCS with a number of plasmapheresis devices and to make our ties with those manufacturers stronger so that installations and transitions to our solution go as smoothly as possible; this integration is part of our most recent filing with the FDA. Our wider range of solutions keeps getting favorable responses from blood and plasma collection organizations throughout the United States, Europe, and Asia, and we are very encouraged by the long-term growth potential of this business. 2025 was a significant step forward, as our Patient Affordability business scaled up and became a key driver of growth and profitability, while our plasma business kept serving as a stable foundation. We think we are still in the early stages of our patient affordability opportunity and are entering 2026 with strong momentum to build on. With that, I'll hand it over to Jeff for more details on our quarterly and full year-end financial results.

Jeff Baker executive
#4

Thanks, Mark. Hello, everyone, and good afternoon. As Mark pointed out, our Q4 and full-year numbers show significant expansion in Patient Affordability along with the initial gains we're getting from operating leverage throughout the platform. Across 2025, total revenues rose 40.5%, reaching $82 million. Revenue from the pharma industry climbed 167.8% to $33.9 million, powered by 55 net patient affordability programs that went live over the last 12 months, plus a matching rise in monthly management fees, setup fees, claim processing fees and other billable services including dynamic business rules and customer service contact center support. Process claims grew by more than 79%. This expansion mirrors the ongoing buildout of our platform and rising demand for solutions that enhance patient access while assisting manufacturers in managing their co-pay assistance spending more effectively. Plasma revenue grew 4% to $45.6 million, mainly from 115 net plasma centers brought on over the last 12 months, partially offset by lower average plasma donations per center since plasma inventory levels stayed elevated for much of 2025. That produced a decrease in our average monthly revenue per center relative to the same period a year earlier. We closed the year with 595 centers, up from 480 centers at the close of 2024. Other revenue rose by $671,000, or 36.2%, largely from greater usage and more cardholders in our payroll, retail and corporate incentive programs. Even more significant, we're starting to realize the advantages of operating leverage across the business. Total operating expenses came to $41.4 million, up 32.6%, which is well under the revenue growth we saw, and combined with our gross profit margin improving to 59.4% from 55.1%, pushed our operating margins to 9% from 1.7% a year earlier. We've hit a key inflection point where our fixed cost base can sustain substantial scalability without corresponding expense increases, so we anticipate additional gains in these metrics through 2026. That aligns with what Mark said before: as patient affordability takes up a bigger share of our business, we expect margins and operating leverage to keep improving. A few other key points on the fourth quarter and full year results: in Q4, earnings before taxes rose to $2.5 million from $1.2 million in the same period last year. Fourth quarter net income took a hit from a higher effective tax rate of 45.4%, cutting earnings per share by $0.02 per fully diluted share versus the prior period. Fourth quarter adjusted EBITDA, a non-GAAP measure that adds back stock compensation to EBITDA, came in at $5.4 million, or $0.09 per diluted share, compared with $2.9 million, or $0.05 per diluted share, a year earlier. The fully diluted share counts used for the per share calculations this quarter were $61.6 million and $55.5 million, respectively. We ended the year holding $21.1 million in cash, nearly twice what we had a year ago. That leaves out any effect on the pass-through receivables and payables tied to our pharma patient affordability business that come up from time to time; operations, plus our Gamma acquisition, are still funded entirely by operating cash flow, with 0 bank debt. Now for our 2026 outlook. Revenue should land between $106.5 million and $110.5 million, which works out to 30% to 35% growth versus last year, split evenly between plasma and pharma, with other revenue adding $2.5 million. Given how seasonal both of our main health care businesses are, plasma revenue should be weakest in the first quarter as tax refunds go out and then build through the rest of the year, whereas pharma revenue should peak in the first quarter and step down over the remaining quarters as patient affordability claims taper off. This outlook captures the momentum we keep seeing in our Patient Affordability business, which should stay the main growth engine. Gross profit margins should come in at 60% to 62%, reflecting a bigger revenue contribution from our pharma patient affordability business. Operating expenses should rise 20% compared with 2025 as we keep investing in people and technology. Within that figure, depreciation and amortization should be $9.5 million to $10 million, and stock-based compensation should be roughly $5.5 million. With our sizable unrestricted and restricted cash balances and where interest rates sit today, we should bring in interest income of about $3.1 million. Our full year tax rate should fall between 22.5% and 25%. Net income should almost double from 2025, landing in a range of $13 million to $16 million, or $0.21 to $0.26 per diluted share, and adjusted EBITDA should land between $30 million and $33 million, or $0.49 to $0.53 per diluted share. We estimate 62.3 million fully diluted shares for the year. For the first quarter of 2026, revenue should be $27 million to $27.5 million, a 45.2% to 47.8% increase over first quarter 2025, and we should exit the quarter with 137 active patient affordability programs and 589 plasma centers. Margins should expand across the income statement relative to the same period last year, translating to an operating margin of 20% to 22%, a net margin of 17% to 19%, and an adjusted EBITDA margin of 34.5% to 36.5%. Fully diluted earnings per share should be $0.07 to $0.08, and adjusted EBITDA per share should be $0.15 to $0.16. All in all, our outlook shows continued strong growth led mainly by our patient affordability business, plus more margin expansion as we scale; with that, I'll hand the call back to Kevin for questions and answers.

Jacob Stephan analyst
#5

Congratulations on a strong quarter. I appreciate the details you provided regarding the pharmaceutical sector. There's one item I was hoping to discuss a bit; we have been picking up on some signals from pharma service providers and — that drug makers have been somewhat quieter lately when it comes to new projects. I'm curious whether you've noticed any shift in how your pharmaceutical manufacturers are behaving across the past few months?

Matt Turner executive
#6

Not at all. This is Matt Turner speaking. I'd say the situation is quite the reverse. Had you been over at JPMorgan and heard what was being discussed there, no one is putting the brakes on anything. We were earlier listening to Dave Ricks, who leads Lilly, and he brought up the billions of dollars being poured into AI and the reality of completing a transaction every 9 days, and practically every presentation given there truly signaled no deceleration whatsoever. Every company's pipeline is exceptionally robust at present. Nearly all manufacturers have some version of a weight loss or GLP-1 category offering in development. The FDA calendar for PDUFA in this year appears very favorable. So honestly, I don't perceive any deceleration. I'd say the drive toward innovation is expanding on the whole. And I believe that's clearly what we've aimed to deliver across the past 7 years while we constructed this vertical, really focusing on the innovation aspect. So no, from where we sit I don't observe any deceleration whatsoever, particularly not within the patient affordability segment.

Jacob Stephan analyst
#7

All right. And perhaps — I realize you already mentioned the GLP-1 opportunity somewhat. What does that look like on your end, I'd like to know. Are any GLP-1s currently on the platform for you folks? And what's your thinking on going after that market in the future?

Matt Turner executive
#8

Yes. So here's the thing — of the 2 bigger GLP-1s indicated for weight loss, we carry none <<inaudible>> the diabetes medications we do have; mostly those are retail plays, and we're definitely pushing. In that space we've been pushing; those drugs have now been on the market for a little while. When you examine those products too, they're very much — far more of a DTC product rather than your traditional co-pay-type product; it isn't that co-pay offers don't exist, because they do. Yet a very small subset of that actual volume is what's moving through co-pay. So on a GLP-1 product used for weight loss, there isn't a ton of upside. On the diabetes side, there would be — we have one client that has a GLP-1 product. I believe we're in — that's coming to market. I believe we're in an excellent position to win that business, since we do hold a very good portion of their retail as well as almost all of their specialty products; so I believe we're in a very good spot to pick up a GLP-1 within the next 12 to 18 months; and I believe that's as much as I can really say there. I don't — we don't have any commitment saying that it's ours or anything, and plus we don't know what the volume is going to look like there; but yes, we're certainly trying to make inroads to get access to more of those programs.

Jacob Stephan analyst
#9

Understood. Then perhaps one final item from me. Jeff, you said something interesting regarding fixed costs possibly leveling off, with few additions really required. Looking at the numbers, that seems to suggest a quarterly cost base of roughly $22 million to $23 million. Could you provide a bit more detail on that?

Jeff Baker executive
#10

Sure. The remark was really about — when we discuss fixed costs, that means the underlying cost of what our company was in 2025; we therefore examined our OpEx, which came to $41 million. The extra expense we must layer in moving forward as the company expands is definitely far smaller than it used to be historically. Looking at 2024, we were pushing SG&A growth that largely moved in step with revenue growth. In 2025, there were really strong gains on that front. For 2026, we believe there is still additional operating leverage to capture from that business. So as you examine it, we will work hard to keep our costs in check. We anticipate SG&A increasing only 20% — 20%. And once you dig deeper, remember that a portion of that increase stems from the acquisition completed in March, <<inaudible>> end for a full year in 2025. That means you get a whole year of amortization in 2026. Beyond that, stock comp rises by roughly $1.5 million year-over-year; so take those 2, whichever way you prefer to view it and strip it out or whatever, yet our controllable SG&A truly appears quite leverageable.

Gary Prestopino analyst
#11

I wasn't able to jot it down quickly enough — was it about 137 pharma programs that you expect to have when Q1 ends?

Jeff Baker executive
#12

That's right, yes.

Gary Prestopino analyst
#13

And then — for the plasma, what was that figure you mentioned? 589, right?

Jeff Baker executive
#14

That's right, 589. During the first quarter, a competitor acquired 5 of our centers. So those went to them, and on top of that, one center shut down. That gives you the 6 centers.

Gary Prestopino analyst
#15

All right. All right. That works. Now, circling back to what you mentioned regarding GLP-1s compared with your expensive branded medications — is there any variation in the revenue per claim there, if what you're handling is, for lack of a better term, not truly a specialty drug, such as a cancer or oncology treatment?

Matt Turner executive
#16

Yeah. So every claim category, correct, will carry its own possible transactional charges attached to it. When you examine the special — and I'd say that on the whole, if you simply take a baseline, let's say a pharmacy claim or a medical claim, specialty versus pharmacy doesn't really make a difference, on that claim we're going to earn a processing fee, we're going to earn roughly the same amount. Yet once you consider the bolt-ons that occur within the specialty segment, they build up quite fast. A dynamic business rule claim is worth much more to us than merely the single co-pay claim. So although the volume for retail products such as GLP-1s or any of the cardiovascular drugs, if you look back over time at like <<inaudible>> certainly, there's substantial volume in that area, but your opportunity to make — to sort of add the extra functionality capable of producing bigger revenue, that simply isn't present on the retail side, which is among the reasons we strongly pursue the specialty segment since we can earn significantly more on 1,000 DBR claims than we can on, let's say, 20,000 retail claims. So profit potential and even bottom line margin is much better within the specialty segment. With that said, we are working to bring on additional retail brands so that we hold a very balanced and comprehensive product portfolio.

Peter Heckmann analyst
#17

I had one more question, Jeff, regarding how you're approaching the 2026 guidance — you mentioned plasma and pharma each contributing equally. My assumption is that you meant that in terms of revenue dollars. If that's right, it still implies a fairly notable step-up on the plasma side. From your prepared remarks, I didn't catch the reason that would be the case, so could you give us a bit more detail on whether it reflects a higher revenue percentage or expectations of a substantial net increase in centers during the year?

Jeff Baker executive
#18

Yes. So — sorry.

Mark Newcomer executive
#19

No, you go first.

Jeff Baker executive
#20

Regarding what I said about revenue — that remark applied to equal business income coming from both the plasma side and the patient portability, or pharma, side. As you may remember, one key factor on the plasma side is that we had 132 centers in June and July. Those will remain uncomped until that point, meaning midyear. So obviously, plasma growth will look considerably stronger across the first half of the year than it will across the second half. My view on plasma hasn't shifted: in a normalized year, it grows roughly 5%, and it's an excellent cash cow that we run the business around accordingly.

Mark Newcomer executive
#21

Let me add some further detail regarding the growth we saw in plasma revenue. Thanks to the most recent hardware upgrades, collection efficiencies have improved, and that hands the typical plasma center roughly 10% more capacity. So a useful way to think about it is that for each 10 centers, a collector is now able to obtain the capacity of 11 centers, and because of that, the need to open new centers is going down. So that simply — it allows them to collect a greater amount.

Peter Heckmann analyst
#22

That's useful. All right; turning now to the new BECCS system. Has the FDA said anything yet, or do you have any sense of when that review might wrap up?

Mark Newcomer executive
#23

Right. At the moment it's being reviewed; we're anticipating a response from them inside 60 days; that's really all I can say for now; but up to this point, things look very encouraging. We've already entered the substantive review phase with them.

Jon Hickman analyst
#24

Can you help us understand the pharma side, specifically your segment of that market? How large is the TAM? And where are we in terms of growth — second inning, third inning? Could you expand on that?

Matt Turner executive
#25

Sure. This is Matt. We tend to hold back on providing a TAM, since it's really hard to do that for something where you simply can't determine with precision — the dollars get tied up in marketing budgets and other things, and no one reveals what they actually pay these vendors. So our estimate puts the TAM at any point in time somewhere from $500 million to $850 million. With certain offerings we have, particularly dynamic business rules that we're promoting, we believe that TAM is moving upward, because we can bring in revenue from some of these distinctive offerings we're introducing. And as we keep developing this, adding additional features and additional products, we believe the TAM could grow even more, reaching as high as $1 billion. On the question of which inning we're in, my view is that it's the first inning. A great deal of growth potential remains. Nothing appears to be slowing down regarding new program acquisition; and if you examine our year-over-year growth, not only in dollar terms, right, but also considering the quantity of programs we're adding. Last year, it was one every 6-point-something days that we were launching a new program. And hopefully, this year, we'll have comparable metrics when it comes to the number of programs we're bringing in; but we are not close to the middle of this at all. We're very much at the start. And I believe we'll keep seeing very strong growth from this vertical for many years ahead.

Jon Hickman analyst
#26

A follow-up from me. Is this an open invitation for rivals to step in? I mean, are folks beginning to notice how you're going about it?

Matt Turner executive
#27

Well...

Mark Newcomer executive
#28

Yeah, competition has honestly always existed.

Matt Turner executive
#29

Yeah, that's true...

Mark Newcomer executive
#30

So basically, what we did was enter this space and take the rivals head-on. And through delivering fresh capabilities and additional features into the market, that's one of the factors behind us landing these deals.

Matt Turner executive
#31

Yeah. This business was really outdated and had basically turned into a commodity. People looked at it like grabbing a product off a shelf. That opened the door for certain manufacturers. Naturally, they like it when things such as maximizers and accumulators pose a real danger to their profitability. That danger has grown larger. Innovation was clearly needed. Sadly, the legacy data source in this sector simply never responded. So sure, some new entrants are appearing; that's what happens whenever an industry is ready for disruption. The upside for us, I'd argue, is that we got out in front of it, and we even drove much of that disruption ourselves. When you examine the way we've sold into this sector, we genuinely stirred things up and pushed manufacturers to reconsider what a co-pay program ought to do overall and how they ought to fund them. The open book pricing we introduced, where we aren't earning questionable money without disclosing how we get compensated — that truly disrupted this market. And if you look at our growth engine, go back to — I believe it was 2023, in June, July, when we released a webinar about pricing transparency and plenty of related topics, that really helped launch us, since we demonstrated to the industry that a better approach exists. You can still earn money. You can still have whatever you require, only we can do it without secretly taking you for everything you've got, which is what many other rivals were doing.

Jeff Baker executive
#32

Also, Jon, if we consider what sets us apart from rivals, that's definitely a major one. There's another as well — and since we're a payments company, we tend to overlook it, but our rivals lack comparable visibility into the programs their pharma clients run, the way we have it. What I mean is, a web portal is provided by us to our clients; they log in, and bank balances are visible to them, transaction data is visible to them. A great deal of information is available to them through us, which lets them determine whether their program is performing well; and we treat that as a given. For a payments company, it's more or less table stakes, yet our other rivals lack it since payments isn't their business. And finally, there are the dynamic business rules. I really can't emphasize enough that with 97% efficacy on first fill, which is entirely agnostic to the consumer receiving their drug, we can determine whether that transaction ties to a maximizer program or not — that's enormous. It's unheard of, and no one else in the market possesses that technology.

Jon Hickman analyst
#33

All right. Just one more thing I'd like to ask. So Matt, on this part of the company, what concerns you the most?

Matt Turner executive
#34

That's a hard question. I'm not sure that at this moment, there's really much that worries us. Things are — quite encouraging on our end. When you consider everything we've developed, I'd say, if you go back 3 years, a great deal of it centered on staffing and the question of how we'd grow this internally through people. Back then it was about locating talent we could recruit and who could assist the organization in expanding. And over the past few years, that's exactly what we've been doing. We put a great deal of time and effort into attracting the right individuals and building a route for those who were truly strong to advance within the company. And with that now established, when you look at the 55 programs we added last year, people weren't a problem for our growth; we'd already organically constructed the systems for that. So we could simply pull individuals in and place them where they belonged; we now have training curriculums that are set up. It's turned into a far simpler task for us. So I'd say, at this point I don't truly have any anxieties. Everything is favorable for us at present; and we're eager for the ongoing growth we're experiencing. We're excited to build further on the partnerships we already have.

Gary Prestopino analyst
#35

Yeah. I've got one more question to ask. Mark, on the patient affordability side, did you provide any sense of what your pipeline looks like? What I mean is, at certain points, you've mentioned being fairly sure that you'd finish the year with a certain number of programs. Maybe you could just address that.

Matt Turner executive
#36

Matt here; I'm not aware that we've ever provided that kind of guidance this early in the year, and I'd also point out that for the majority of our opportunities, our selling cycle runs around 90 days. Right now, we have a clear picture of how the pipeline looks across a number of opportunities. My guess is we'd likely address that once we're a bit further into the year, after the Asembia conference has wrapped up, that sort of thing; that's genuinely the point where we begin to pin down what we expect the pipeline to be from now until year-end, and it also lets us more thoroughly assess the FDA PDUFA calendar and determine which opportunities from it we think are actually winnable for us. So yeah, providing a program count this early in the year isn't something I think we can do, but with any luck, we'll be able to next quarter if all goes well.

Gary Prestopino analyst
#37

All right. You folks are performing quite strongly. And clearly, equities have been something of a small-scale catastrophe across the past 2 months or so. It certainly appears that the business's underlying fundamentals aren't being mirrored by the share price. So I'm curious — when you're out meeting with investors, is the issue that they fail to grasp what's happening at your company? Or perhaps there's a sense that AI could take over your capabilities involving your dynamic business rules? What exactly can you identify as the source of some of this reluctance from investors to fully appreciate the story?

Jeff Baker executive
#38

Yes, Gary. So whenever we speak with investors, everyone clearly gets the plasma business. It's somewhat comparable to retail same-store sales kinds of metrics. And I believe the largest thing is that the market has adopted a show-me posture regarding the operating leverage coming from the patient affordability business. Right now there's plenty of noise out there, always involving direct-to-consumer. If you recall the period when Donald Trump was going to fix every pricing problem. He launched his own Donald Trump pharmacy along with his direct-to-consumer initiative. And honestly, they rolled it out, I believe there were 30 drugs or so, whatever it was. We had 2 of those listed there; and the pricing — the pricing on that direct-to-consumer side for — and again, those are cash paying customers, ended up cheaper when you had insurance compared with paying directly to the consumer; so — and bear in mind, there are roughly 160 million people out there covered by private insurance. That's precisely what these co-pay programs exist for. They're not meant for the cash paying customer. So I think there has — I think people don't always grasp co-pay. I know as a matter of fact, they don't grasp co-pay. And we're going to work very hard in 2026 to sharpen that message so people understand that a co-pay does exist. The co-pay genuinely exists. There's a market for co-pay. We possess a better mousetrap that nobody else has, and it's appearing in the numbers. And this year in 2025, you certainly witnessed the operating leverage that's possible. I mean, our operating margin climbs from 1.7% to 9%, and that's not insignificant; and then according to the guidance I've provided, we anticipate that rising substantially in 2026 and beyond. So I can't dictate the stock price or the investor community or whatever, but I think the numbers speak for themselves and in the end the market is efficient over the long term.

Matt Turner executive
#39

Also, let me mention something: when you take a look at the other businesses competing with us out there, if you examine <<inaudible>> and you examine McKesson, each of them has co-pay products, correct? Yet that piece is so minor relative to their overall financials that it never comes up during an earnings call. That means we're basically the first publicly traded company discussing this openly, and analysts are attempting to digest it, since for our company it isn't a trivial item. When it comes to McKesson and <<inaudible>>, this accounts for an extremely tiny slice of what they hold overall. So I believe it has also allowed the Street an opportunity to catch up and recognize this as a fresh new product available in the market; and ideally, they will support it, and more individuals will grasp it. And my sense is the private equity world gets it too. Quite a few private equity funds have bought similar assets through private transactions. Were you to examine the private markets, plenty of M&A deals are taking place in this area — not only co-pay but patient services broadly. Things shift all the time; so we got the opportunity to head down to the Cantor HCIT conference, sit with many folks, and simply hear their perspectives. And it's — there's significant activity in this area. It simply isn't happening in the public market; so I think that's one of the challenges we face as well, which is clarifying that and helping people realize that this is a — there's a larger sum of money involved here than what it appears to be from our perspective.

Gary Prestopino analyst
#40

Regarding your competitive edges — those dynamic business rules — does any sentiment exist out there? And I suppose this is a foolish AI question. Might AI in some way take over what you're accomplishing in the market?

Matt Turner executive
#41

So, I mean, I sort of — when clients and I speak by phone, I tell them jokingly that AI is capable of anything you could imagine. I simply don't know the timing of when it will manage that. I mean, AI — we don't see AI as a danger. Internally, we're working to develop our own systems built on AI to assist in making our algorithm more powerful, so we detect maximizers and accumulators with greater ease. Another thing worth mentioning is that merely because they alter their approach onetime doesn't guarantee we won't be right there altering ours to locate it, and without diving into excessive specifics; yet once a single patient is mine, and I'm aware that maximizer affects that patient, I can — regardless of what the plan does, I can work backward to that patient since I know yesterday they were a maximizer patient; today they're likely still a maximizer patient. Thus we don't believe that poses much of a danger to our business model; we view AI as being on our side, genuinely a plus, and we'll be rolling out more of it regarding patient affordability to help us achieve a stronger, more robust product throughout our vertical.

Mark Newcomer executive
#42

Appreciate that, Kevin. As we wrap up, 2025 brought us solid performance. Our confidence in the strategy we're pursuing for the long haul hasn't wavered. Thanks to each of you for being here with us today, and we can't wait to talk with you once more in Q1.

Operator operator
#43

Thanks for joining us, everyone. That wraps up today’s teleconference and webcast. At this point, you’re welcome to disconnect your line, and we hope the rest of your day is wonderful. We appreciate your participation today.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Paysign, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Paysign, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.